Home > Boards > US OTC > Biotechs >

Hepion Pharmaceuticals, Inc (HEPA)

HEPA RSS Feed
Add HEPA Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/12/2022 11:10:31 AM - Followers: 86 - Board type: Free - Posts Today: 0


 

Hepion Pharmaceuticals (Nasdaq: $HEPA) is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).

Hepion announced top line data from the low dose cohort in the Company's Phase 2a ‘AMBITION' clinical trial of CRV431, an oral, once daily novel cyclophilin inhibitor. This Phase 2a study is continuing with the higher dose of 225 mg CRV431, with NASH patient dosing expected to be completed in Q1-2021.In 2021, of the more than 300 million people living with HBV infection, 10.5% (27 million) were aware of their infection. Non-alcoholic Fatty Liver Disease (NAFLD) affects up to 25% of people in the United States. There are currently no medicines that can cure non-alcoholic Fatty Liver Disease effectively. The same can be said with HBV. With the momentum growing around hepatitis B drug discovery research, we are closer than ever to a cure.

Fact: The inflows have been massive the last 2 weeks. Reason why In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.

Bottom line The FDA looks for safety first we have the safest NASH drug our efficacy data is better than MDGL & AKRO. there market caps our almost 10x HEPA. Smart savvy biotech investors with deep pockets know this and are accumulating all they can of HEPA at these levels.
One morning we can wake up and see the price has tripled from its 160 market cap. Also they have 120 million in cash burning under 5 million a quarter. Lots of moving parts here. Gilead & Novo in the mix we will see? A new molecule being added to the pipeline. This management team is experienced 100 years total and world renown experts on cyclophilin inhibitors. They brought a FDA approved blockbuster drug to market already.

June 2021 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf

HEPA AI-POWR
https://hepionpharma.com/ai-powr/
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action
https://www.youtube.com/watch?v=CE7es4l1avM

HEPA GLOBAL NASH CONFERENCE PRESENTATION:
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf

HEPA website
https://hepionpharma.com

Chairman of the Board, Gary Jacob, is not just a business guy, he's one hell of a biochemist, and you can bet he has a solid grasp of everything that's going on with Hepion.
He's a key player here!

His background goes way beyond what you ordinarily see on the BOD of little R&D biotechs. You might see those with his research background on Scientific Advisory Boards, but they wouldn't have a fraction of the business expertise he's got.
Hepion has the whole package, with this guy!!

Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board
https://www.globenewswire.com/news-release/2019/08/07/1898563/0/en/Hepion-Pharmaceuticals-Welcomes-Dr-Stephen-Harrison-to-its-Scientific-Advisory-Board.html

Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
Todd Hobbs coming to Hepion. It was published in December. Hobbs' primary focus has always been on diabetes, and I have said many times that there's a blockbuster reason for him leaving his position as Vice President, Chief Medical Officer at Novo Nordisk, a USD 190B global pharmaceutical behemoth, after nearly 17 years there, to come to tiny Hepion.
I believe we'll be hearing about CRV431 in the treatment of diabetes, as it has the highest known potency of any reported cyclophilin inhibitor known, by a wide margin...
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/

Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash

Currently trading at $2.2 due to a public offering of 44.000.000 shares $2

According to analysts' consensus price target of $80.00, Hepion Pharmaceuticals has a forecasted upside of 3,503.6% from its current price of $2.22.

$HEPA

HEPA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
HEPA News: CORRECTING and REPLACING - Hepion Pharmaceuticals, Inc. 04:53 AM
HEPA News: Current Report Filing (8-k) 04:45 AM
HEPA News: Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress 04:00 AM
HEPA News: Quarterly Report (10-q) 05/16/2022 12:46:14 PM
HEPA News: Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial 05/03/2022 04:00:00 AM
News News Alert: CORRECTING and REPLACING - Hepion Pharmaceuticals, Inc. 05/27/2022 04:53:57 AM
PostSubject
#1938   Discount. lol most of the market is printing BooDog 05/12/22 11:10:31 AM
#1937   LMAO CreampieMafia 05/02/22 03:05:05 PM
#1936   Short squeeze coming as well. Filings next week Ruffieruff 03/25/22 02:56:22 PM
#1935   Potential breakout in the making. BooDog 03/25/22 02:42:07 PM
#1934   Just like his money long gone bball71 03/24/22 05:22:16 PM
#1933   I wonder where the account holder for “fress” CreampieMafia 03/07/22 05:01:38 PM
#1932   Nice steady increase of late in a challenging market. couldbebetter 03/04/22 07:11:38 AM
#1931   $CTRVW will pay big here in time. I’m Moose Cat 03/02/22 08:44:16 PM
#1930   The place to make money with $HEPA is Moose Cat 03/01/22 03:14:48 PM
#1929   HEPA up 10% what’s going on??? Bertsllc 03/01/22 12:40:00 PM
#1928   New target price $4.75 Esa 03/01/22 10:36:10 AM
#1927   Sorry, I was way off, current holdings: Esa 02/10/22 02:17:47 PM
#1926   HEPA Analyst Ratings Esa 02/10/22 01:59:20 PM
#1925   Vanguard Group increasing to their position, they hold Esa 02/10/22 11:57:17 AM
#1924   That’s good. We need you around. I’ve been Ruffieruff 01/27/22 04:57:59 PM
#1923   Still holding and considering to add soon. StocktraderDK 01/27/22 04:56:23 PM
#1922   https://seekingalpha.com/article/4480831-hepion-pharmaceuticals-facing-the-momen $pyrodog 01/21/22 01:00:59 PM
#1921   You’ve vanished just like our Hawaiian buddy. Did Ruffieruff 01/20/22 07:59:07 PM
#1920   https://investorshub.advfn.com/uimage/uploads/2012/10/25/yscznlmao.gif[/img Bertsllc 01/18/22 05:51:33 AM
#1919   Still on vacation lol CreampieMafia 01/10/22 06:16:01 PM
#1918   $HEPA: CRV431 now known as RENCOFILSTAT makinezmoney 01/07/22 07:35:41 AM
#1917   This has to be one of the toughest Ruffieruff 01/02/22 08:29:44 AM
#1916   Over sold, i hope so Bertsllc 01/01/22 08:04:27 PM
#1915   4 more days until tax loss selling ends Bourbon_on_my_cornflakes 12/27/21 04:18:02 PM
#1914   Someone Big is pounding this stock. A group Bertsllc 12/22/21 03:50:22 PM
#1913   Here comes the Santa rally, break 1.39 and Esa 12/22/21 11:59:06 AM
#1912   Give it time. That's good for investors to mpunklil 12/22/21 11:14:07 AM
#1911   It's a damn shame. Wasting all these good Bertsllc 12/21/21 09:59:11 AM
#1910   Excellent!! Hepion Pharmaceuticals Announces FDA Clearance of IND BooDog 12/21/21 09:01:00 AM
#1909   Another sell the news event? Suppression at Ruffieruff 12/21/21 08:21:54 AM
#1908   Same story every week. Pump then dump. Follow CreampieMafia 12/10/21 02:04:10 PM
#1907   I was right again CreampieMafia 12/06/21 12:38:13 PM
#1906   Gona break a new low again today. What CreampieMafia 12/06/21 09:39:47 AM
#1905   Still in Hawaii bball71 12/04/21 07:56:48 AM
#1904   Certainly nothing exciting but for a market day BooDog 12/03/21 04:53:41 PM
#1903   Big fail lol CreampieMafia 12/03/21 01:20:55 PM
#1902   $HEPA Just so everyone knows that AKRO is StocktraderDK 12/01/21 05:19:32 PM
#1901   Excellent point Giovanni. Companies apply for fast BooDog 12/01/21 07:01:06 AM
#1900   What percentage of fast track drugs get approved? Giovanni 11/30/21 07:56:05 PM
#1899   Robert Foster, PharmD, PhD, Hepion’s CEO, added, “This BooDog 11/30/21 06:11:15 PM
#1898   OK lolol CreampieMafia 11/30/21 04:59:01 PM
#1897   I'm playing more off the technicals with a BooDog 11/30/21 04:58:31 PM
#1896   Thats when the OS was at 12 mil CreampieMafia 11/30/21 04:07:15 PM
#1895   $HEPA: ROTH Capitals Last update was PT of $14 makinezmoney 11/30/21 01:28:01 PM
#1894   In some at $1.17 tw0122 11/30/21 01:23:07 PM
#1893   $HEPA: We shoud be getting an ANALYST upgrade........... makinezmoney 11/30/21 01:11:39 PM
#1892   Ok but theyre not. They are red. LOL CreampieMafia 11/30/21 12:31:45 PM
#1891   1.15 triple bottom. Trip and rips can BooDog 11/30/21 12:21:44 PM
#1890   LETS BREAK 1.15 lolol CreampieMafia 11/30/21 12:16:59 PM
#1889   What you got to say now? Back to CreampieMafia 11/30/21 11:39:27 AM
PostSubject
Consent Preferences